Top Rapid Plasma Reagin Test Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Rapid Plasma Reagin Test Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Rapid Plasma Reagin Test industry players.

Rapid Plasma Reagin Test Market Competitive Landscape

Rapid plasma reagin test providers should focus on raising more awareness regarding syphilis and STI testing to boost their business scope. Investing in the R&D of novel portable and rapid tests is also a prominent opportunity for companies as per this global rapid plasma reagin test market analysis.

Reducing the test and result times for novel rapid plasma reagin tests is slated to generate new opportunities for market players. Here’s a startup that has the potential to augment the rapid plasma reagin test industry in the long run.

  • Mylab Discovery Solutions: Based in Pune, Maharashtra, India the startup has developed rapid diagnostic kits for the early detection of sexually transmitted infections, including syphilis. The 2016-founded company’s Syphilis Antibody test detects antibodies (IgG, IgA, IgM) to Treponema pallidum, facilitating early diagnosis. These tests are designed for ease of use, can be stored at room temperature, and are deployable at the point of care, making them suitable for resource-limited settings.

Top Player’s Company Profiles

  • Thermo Fisher Scientific Inc. (USA) 
  • Danaher Corporation (USA) 
  • Abbott Laboratories (USA) 
  • F. Hoffmann-La Roche AG (Switzerland) 
  • Siemens Healthineers AG (Germany) 
  • Bio-Rad Laboratories, Inc. (USA) 
  • Merck KGaA (Germany) 
  • Quest Diagnostics (USA) 
  • Cardinal Health, Inc. (USA) 
  • bioMerieux SA (France) 
  • Becton, Dickinson and Company (BD) (USA) 
  • Sekisui Diagnostics (USA) 
  • Meridian Bioscience, Inc. (USA) 
  • Arlington Scientific Inc. (USA) 
  • Immunostics Inc. (USA) 
  • Novacyt Group (France) 
  • Trinity Biotech plc (Ireland) 
  • Atlas Medical GmbH (Germany) 
  • Sclavo Diagnostics International S.r.l. (Italy)

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Rapid Plasma Reagin Test Market size was valued at USD 1.89 Billion in 2023 and is poised to grow from USD 2.08 Billion in 2024 to USD 4.18 Billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

Rapid plasma reagin test providers should focus on raising more awareness regarding syphilis and STI testing to boost their business scope. Investing in the R&D of novel portable and rapid tests is also a prominent opportunity for companies as per this global rapid plasma reagin test market analysis. 'Quotient Limited (Switzerland)', 'CareDx Inc. (U.S.)', 'Agena Bioscience, Inc. (Mesa Laboratories, Inc.) (U.S.)', 'DIAGAST (U.S.)', 'Illumina, Inc. (U.S.)', 'Grifols, S.A. (Spain)', 'Immucor, Inc. (U.S.)', 'Bio-Rad Laboratories, Inc. (U.S.)', 'Thermo Fisher Scientific Inc. (U.S.)', 'Merck KGaA (Germany)', 'QIAGEN (Netherlands)', 'Beckman Coulter, Inc. (Danaher) (U.S.)', 'QuidelOrtho Corporation (U.S.)'

Increasing incidence of chronic diseases coupled with high health and wellness awareness has led to robust increase in demand for preventive healthcare. Early detection of syphilis through routine screening helps prevent complications and curtails the spread of the infection. Healthcare providers are integrating RPR testing into standard preventive care protocols, especially for high-risk groups. This proactive approach aligns with broader public health goals of reducing STI prevalence and promotes regular screening.

Integration of RPR Testing with Multiplex Diagnostics: The integration of RPR tests into multiplex diagnostic platforms is a growing trend that enhances efficiency in STI screening. Multiplex tests simultaneously detect multiple infections like HIV, syphilis, and hepatitis from a single sample. This reduces testing time, costs, and logistical complexity, especially in resource-limited settings. This rapid plasma reagin test market trend supports wider adoption of RPR by embedding it into comprehensive testing strategies, offering a holistic approach to STI management and improving overall diagnostic coverage.

Why is Adoption of Rapid Plasma Reagin Test High in North America?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Rapid Plasma Reagin Test Market
Rapid Plasma Reagin Test Market

Report ID: SQMIG35D2313

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE